Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation
Marina Serper, Ethan M. Weinberg, Jordana B. Cohen, Peter P. Reese, Tamar H. Taddei, David E. Kaplan – 8 April 2020
Letter to the Editor: Thromboelastography‐Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?
Massimo Primignani, Giulia Tosetti, Armando Tripodi – 8 April 2020
E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice
Eva Moreno, Mathilda J.M. Toussaint, Saskia C. Essen, Laura Bongiovanni, Elsbeth A. Liere, Mirjam H. Koster, Ruixue Yuan, Jan M. Deursen, Bart Westendorp, Alain Bruin – 7 April 2020
COVID‐19 and liver disease
Jian Sun, Alessio Aghemo, Alejandro Forner, Luca Valenti – 6 April 2020
COVID‐19 and liver disease
Jian Sun, Alessio Aghemo, Alejandro Forner, Luca Valenti – 6 April 2020
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George – 6 April 2020 – Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real‐world studies are needed to inform the impact of widespread DAA treatment on antiviral resistance in the community.
Novel Therapies for Managing Cholestasis
Priscila Santiago, Cynthia Levy – 4 April 2020
Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis
Alessandro Mantovani, Giorgia Beatrice, Andrea Dalbeni – 4 April 2020 – At present, there is scarce information regarding the global prevalence of chronic liver disease in individuals with coronavirus disease 2019 (COVID‐19) disease, which is becoming a global pandemic. The aim of this study was to assess the overall prevalence of chronic liver disease among patients with COVID‐19 disease by meta‐analysing data in observational studies and to investigate the relationship between liver damage and COVID‐19 disease.
Let’s not forget our COVID‐19‐free cirrhotic patients!
Mauro Viganò, Marco Carbone – 4 April 2020
Letter to the Editor: A Prognostic Algorithm Based on Stage of Cirrhosis and Hepatic Venous Pressure Gradient to Improve Risk Stratification After Variceal Bleeding
Ashish Kumar, Praveen Sharma, Anil Arora – 4 April 2020